Ribose (Furanose)

Ribose (Furanose)

SCHEMBL77096

OC[C@H]1O[C@H](O)[C@@H](O)[C@H]1O

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LGALS1 P09382 2/20 0.54
LGALS3 P17931 2/20 0.54
LGALS9 O00182 1/20 0.54
LGALS8 O00214 1/20 0.54
LMNA P02545 3/20 0.44
ALDH1A1 P00352 2/20 0.44
TSHR P16473 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
CA12 O43570 3/20 0.42
CA1 P00915 3/20 0.42
CA2 P00918 3/20 0.42
CA9 Q16790 3/20 0.42
KDM4E B2RXH2 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C19 P33261 1/20 0.42
GBA1 P04062 1/20 0.41
PYGB P11216 4/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ribose (Furanose) SCHEMBL15814845 1.00 LGALS1 (0.54) LGALS1LGALS3LGALS9LGALS8LMNA
Ribose (Furanose) SCHEMBL14349491 1.00 LGALS1 (0.54) LGALS1LGALS3LGALS9LGALS8LMNA
Ribose (Furanose) SCHEMBL447758 1.00 LGALS1 (0.54) LGALS1LGALS3LGALS9LGALS8LMNA
Ribose (Furanose) SCHEMBL16199379 1.00 LGALS1 (0.54) LGALS1LGALS3LGALS9LGALS8LMNA
Ribose (Furanose) SCHEMBL24087736 1.00 LGALS1 (0.54) LGALS1LGALS3LGALS9LGALS8LMNA
Ribose (Furanose) SCHEMBL66645 1.00 LGALS1 (0.54) LGALS1LGALS3LGALS9LGALS8LMNA
Ribose (Furanose) SCHEMBL23017520 1.00 LGALS1 (0.54) LGALS1LGALS3LGALS9LGALS8LMNA
Ribose (Furanose) SCHEMBL109435 1.00 LGALS1 (0.54) LGALS1LGALS3LGALS9LGALS8LMNA
Ribose (Furanose) SCHEMBL12878699 1.00 LGALS1 (0.54) LGALS1LGALS3LGALS9LGALS8LMNA
Ribose (Furanose) SCHEMBL7618455 1.00 LGALS1 (0.54) LGALS1LGALS3LGALS9LGALS8LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1262 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10588962-B2 Carbohydrate-glycolipid conjugate vaccines MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2020-03-17 US claimed
US-20150238597-A1 CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2015-08-27 US claimed
US-20150216985-A1 ENDOSPORE COMPOSITIONS AND USES THEREOF Annuary Healthcare Inc. 2015-08-06 US claimed
EP-2827899-B1 POLYSACCHARIDE ANTIGEN-GLYCOLIPID CONJUGATE VACCINES MAX PLANCK GES ZUR FÖRDERUNG DER WISSENSCHAFTEN E V (DE) 2015-08-05 EP claimed
EP-2827899-A1 CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2015-01-28 EP claimed
WO-2013178236-A1 CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. (DE) 2013-12-05 WO claimed
WO-2013139803-A1 CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2013-09-26 WO claimed
US-20120108533-A1 NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) 2012-05-03 US claimed
CN-101219114-B Pennogenin compounds solid state molecule dispersion preparation YUNNAN BAIYAO GROUP CO LTD 2010-06-02 CN claimed
CN-101181288-B Solid-state molecule disperse preparations of pennogenin series compounds YUNNAN BAIYAO GROUP CO LTD 2010-06-02 CN claimed
CN-1562064-A New use of saponin compound for treating cardiovascular disease CHINESE MEDICINES & NATURAL ME (CN) 2005-01-12 CN claimed
EP-1144425-B1 DERIVATIVES OF MONOSACCHARIDES AS CELL ADHESION INHIBITORS RANBAXY LAB LTD (IN) 2004-06-16 EP claimed
US-6693178-B2 HALOGENATED BENZYL ETHER GALACTOPYRANOSIDE, GLUCOPYRANOSIDE, RIBOFURANOSIDE OR XYLOFURANOSIDE DERIVATIVES; STABLE, EASILY REMOVED MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2004-02-17 US claimed
CN-1414010-A Cardiac glycoside type compound for treating carcinosis and its preparation method SHENZHENG CHINESE MEDICINE AND (CN) 2003-04-30 CN claimed
US-6329344-B1 UREA DERIVATIVE OF ALKYLENE DIOXYFURAN ETHERS RANBAXY LABORATORIES LIMITED (IN) 2001-12-11 US claimed
EP-1144425-A1 DERIVATIVES OF MONOSACCHARIDES AS CELL ADHESION INHIBITORS RANBAXY LABORATORIES, LTD. (IN) 2001-10-17 EP claimed
WO-2000042053-A1 DERIVATIVES OF MONOSACCHARIDES AS CELL ADHESION INHIBITORS RANBAXY LABORATORIES LIMITED (US) 2000-07-20 WO claimed
EP-0668866-B1 ANTI-PROLIFERATIVE AND ANTI-INFLAMMATORY COMPOUNDS: DERIVATIVES OF PENTOSE MONOSACCHARIDES BOSTON LIFE SCIENCES INC (US) 1997-07-30 EP claimed
EP-0668866-A1 ANTI-PROLIFERATIVE AND ANTI-INFLAMMATORY COMPOUNDS: DERIVATIVES OF PENTOSE MONOSACCHARIDES. GREENWICH PHARMA (US) 1995-08-30 EP claimed
WO-1994011381-A1 ANTI-PROLIFERATIVE AND ANTI-INFLAMMATORY COMPOUNDS: DERIVATIVES OF PENTOSE MONOSACCHARIDES GREENWICH PHARMACEUTICALS INCORPORATED (US) 1994-05-26 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150216985-A1 ENDOSPORE COMPOSITIONS AND USES THEREOF CUTA, SUCLG1, CD47 LGALS1 347/4885LGALS3 368/4885LGALS9 1207/4885
US-20150238597-A1 CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES STT3B, STT3A, DDOST LGALS1 176/4885LGALS3 119/4885LGALS9 153/4885
US-20120108533-A1 NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS PNP, TYMP, MTAP LGALS1 4054/4885LGALS3 4516/4885LGALS9 4192/4885
US-10588962-B2 Carbohydrate-glycolipid conjugate vaccines STT3B, STT3A, DDOST LGALS1 176/4885LGALS3 119/4885LGALS9 153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.